Table 3.
Summary of persistence rates with TNFi between 1 and 7 years reported across all identified studies, by geographic region
| Country | Data source | Time point | Treatment | ||||
|---|---|---|---|---|---|---|---|
| Adalimumab | Certolizumab pegol | Etanercept | Infliximab | Golimumab | |||
| Austria | Claims | 1 year [46] | 70% (AS) | – | 83% (AS) | 71% (AS) | – |
| 2 years [46] | 55% (AS) | – | 58% (AS) | 54% (AS) | – | ||
| Belgium | Registries | 5 years [89] | – | – | – | – | – |
| Medical records | 7 years [42] | – | – | – | 36% (RA) | – | |
| Denmark | Registries | 1 year [19, 26, 44, 90] | – | – | 73% (RA) |
71% (RA) 58% (PsA) |
– |
| Finland | Medical records | 1 year [66] | – | – | 83% (JIA) | 80% (JIA) | – |
| 2 years [66] | – | – | 68% (JIA) | 68% (JIA) | – | ||
| 4 years [66] | – | – | 61% (JIA) | 48% (JIA) | – | ||
| France | Medical records | 1 year [91, 92] |
86% (RA) 68.2% (RA and SpA) |
– |
87% (RA) 76% (AS) 63.9% (RA and SpA) |
68% (RA) 78.9% (AS) 63.2% (RA and SpA) |
– |
| 2 years [91, 92] |
66% (RA) 60.2% (RA and SpA) |
– |
68% (RA) 50.8% (RA and SpA) |
46% (RA) 83% (AS) 47.5% (RA and SpA) |
– | ||
| 50 months [91] | – | – | 50% (RA) | – | – | ||
| Greece | Registries | 1 year | 67% (RA) | – | 68% (RA) | 64% (RA) | – |
| 5 years | 43% (RA) | – | 49% (RA) | 31% (RA) | – | ||
| Medical records | 1 year [93] | 83.7% (RA) | – | 70% (RA) | 82.9–84.5% (RA) | – | |
| 5 years [45, 93] |
44.9% (RA) 50% (PsA) |
– | 76% (PsA) | 56.7% (PsA) | – | ||
| 7 years [93] | – | – | – | 32.9% (RA) | – | ||
| Iceland | Registries | 1 year [26] | – | – | – | 66% (PsA) | – |
| Italy | Registries | 3 years [94] | – | – | – | 58% (RA) | – |
| 4 years [95] | 36.4% (RA) | – | 51% (RA) | 37.6% (RA) | – | ||
| 5 years [94] | – | – | – | 41.1% (RA) | – | ||
| Medical records | 1 year [24, 96] |
65.38% (PsO) 79% (RA) |
– |
65.65% (PsO) 76% (RA) |
71.43% (PsO) | – | |
| 2 years [24, 96] |
46.55% (PsO) 60% (RA) |
– |
37.07% (PsO) 61% (RA) |
46.07% (PsO) | – | ||
| 4 years [96] | 27% (RA) | – | 21% (RA) | – | – | ||
| Japan | Registries | 1 year [97] | – | – | 84.6% (RA) | – | – |
| 2 years [54] | – | – | 72% (RA) | – | – | ||
| 3 years [54] | – | – | 67% (RA) | – | – | ||
| Medical records | 1 year [98] | 78.2% (RA) | – | 85.9% (RA) | 73.1% (RA) | – | |
| 2.5 years [98] | 54.5% (RA) | – | 77.7% (RA) | 47.2% (RA) | – | ||
| 5 years [98] | – | – | 61.9% (RA) | 29.8% (RA) | – | ||
| The Netherlands | Registries | 1 year [27] | 74% (PsO) | – | 68% (PsO) | – | – |
| Spain | Registries | 1 year [68] | 67–87% (RA, AS, PsA, JIA, etc.) | – | 76–88% (RA, AS, PsA, JIA, etc.) | – | – |
| Sweden | Registries | 1 year [34] | 57% (RA, PsA and AS) | 55% (RA, PsA, AS) | 56% (RA, PsA, AS) | – | 58% (RA, PsA, AS) |
| 2 years [34] | 40% (RA, PsA and AS) | 40% (RA, PsA and AS) | 39% (RA, PsA and AS) | – | 46% (RA, PsA and AS) | ||
| 3 years [34] | 33% (RA, PsA and AS) | 33% (RA, PsA and AS) | 33% (RA, PsA and AS) | – | 40% (RA, PsA and AS) | ||
| Taiwan | Medical records | 1 year [57] | 83.3% (RA) | – | 91.1% (RA) | – | – |
| UK | Registries | 1 year [22] | 91% (PsA) | – | 86% (PsA) | 71% (PsA) | – |
| 2 years [22] | 70% (PsA) | – | 79% (PsA) | 52% (PsA) | – | ||
| 3 years [22] | 66% (PsA) | – | 65% (PsA) | 43% (PsA) | – | ||
| USA | Claims | 1 year [32, 36, 38] |
47% (RA, PsO, PsA and AS) 45% (PsA) 66-94% (RA) |
– |
42% (RA, PsO, PsA and AS) 50% (PsA) 62.2-89.2% (RA) |
56% (RA, PsO, PsA and AS) 68.9-96.4% (RA) |
– |
The data included in the table include the results from studies reporting data from 1 through 7 years of anti-TNF use. Supplementary Table 1 provides a full list of studies identified, including those reporting values from 0–1 year
AS ankylosing spondylitis, JIA juvenile idiopathic arthritis, PsA psoriatic arthritis, PsO psoriasis, RA rheumatoid arthritis, SpA spondyloarthritis